Antitumor effects of interleukin 2 against advanced renal cell carcinoma and prognosis of the patients by long term follow-up

Mototsugu Oya, K. Marumo, H. Tazaki

Research output: Contribution to journalArticle

Abstract

Eighteen patients with advanced renal cell carcinoma (RCC) were treated by systemic administration of interleukin-2 (IL-2) from March 1986 to October 1988. All of the patients received 1 x 106 units of IL-2 twice a day for at least 4 weeks. Three patients achieved complete response (CR), 10 no change (NC) and 5 progressive disease (PD). Therefore, the response rate was 16.7%. Survival rate was compared with historical control group of 27 patients with advanced RCC in our institution. One, three and five year survival rate of the patients treated with IL-2 was 78%, 44% and 33%, although the historical group was 57%, 19% and 19%. We conclude that IL-2 can improve prognosis of patients with advanced RCC.

Original languageEnglish
Pages (from-to)348-349
Number of pages2
JournalBiotherapy
Volume9
Issue number3
Publication statusPublished - 1995

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Survival Rate
Control Groups

Keywords

  • IL-2
  • renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Antitumor effects of interleukin 2 against advanced renal cell carcinoma and prognosis of the patients by long term follow-up. / Oya, Mototsugu; Marumo, K.; Tazaki, H.

In: Biotherapy, Vol. 9, No. 3, 1995, p. 348-349.

Research output: Contribution to journalArticle

@article{f6753dfd975c4fe2a31c9e561d5c6054,
title = "Antitumor effects of interleukin 2 against advanced renal cell carcinoma and prognosis of the patients by long term follow-up",
abstract = "Eighteen patients with advanced renal cell carcinoma (RCC) were treated by systemic administration of interleukin-2 (IL-2) from March 1986 to October 1988. All of the patients received 1 x 106 units of IL-2 twice a day for at least 4 weeks. Three patients achieved complete response (CR), 10 no change (NC) and 5 progressive disease (PD). Therefore, the response rate was 16.7{\%}. Survival rate was compared with historical control group of 27 patients with advanced RCC in our institution. One, three and five year survival rate of the patients treated with IL-2 was 78{\%}, 44{\%} and 33{\%}, although the historical group was 57{\%}, 19{\%} and 19{\%}. We conclude that IL-2 can improve prognosis of patients with advanced RCC.",
keywords = "IL-2, renal cell carcinoma",
author = "Mototsugu Oya and K. Marumo and H. Tazaki",
year = "1995",
language = "English",
volume = "9",
pages = "348--349",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "3",

}

TY - JOUR

T1 - Antitumor effects of interleukin 2 against advanced renal cell carcinoma and prognosis of the patients by long term follow-up

AU - Oya, Mototsugu

AU - Marumo, K.

AU - Tazaki, H.

PY - 1995

Y1 - 1995

N2 - Eighteen patients with advanced renal cell carcinoma (RCC) were treated by systemic administration of interleukin-2 (IL-2) from March 1986 to October 1988. All of the patients received 1 x 106 units of IL-2 twice a day for at least 4 weeks. Three patients achieved complete response (CR), 10 no change (NC) and 5 progressive disease (PD). Therefore, the response rate was 16.7%. Survival rate was compared with historical control group of 27 patients with advanced RCC in our institution. One, three and five year survival rate of the patients treated with IL-2 was 78%, 44% and 33%, although the historical group was 57%, 19% and 19%. We conclude that IL-2 can improve prognosis of patients with advanced RCC.

AB - Eighteen patients with advanced renal cell carcinoma (RCC) were treated by systemic administration of interleukin-2 (IL-2) from March 1986 to October 1988. All of the patients received 1 x 106 units of IL-2 twice a day for at least 4 weeks. Three patients achieved complete response (CR), 10 no change (NC) and 5 progressive disease (PD). Therefore, the response rate was 16.7%. Survival rate was compared with historical control group of 27 patients with advanced RCC in our institution. One, three and five year survival rate of the patients treated with IL-2 was 78%, 44% and 33%, although the historical group was 57%, 19% and 19%. We conclude that IL-2 can improve prognosis of patients with advanced RCC.

KW - IL-2

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0028903736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028903736&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028903736

VL - 9

SP - 348

EP - 349

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 3

ER -